Johnson & Johnson (JNJ) released its Q2 result on July 18. Despite weaker than expected sales in the quarter, the company delivered better than expected earnings. However, its stock price has declined from the high of $137.08 to below $131 at the end of the trading day today. With its recent acquisitions in the first half of 2017 and the approval of Tremfya a few weeks ago, J&J’s sale and revenue is expected to continue to grow in the near-term. Together with a long history of consistent dividend increase, long-term dividend growth investors can take advantage of the dip to establish their position.

J&J’s sales rose by 1.9% to $18.8 billion in the past quarter. Operational sales increased by 2.9% with a -1% currency impact. Its adjusted EPS was $1.83, an increase of 5.2% from the same quarter last year. It was also above the consensus among analysts.

READ FULL ARTICLE HERE